Society for Basic Urologic Research 2019 Annual Meeting "NOVEL DISCOVERIES IN UROLOGY: BIG DATA TO MICROBIOME"

此应用程序请求支持基础泌尿外科研究学会（SBUR）2019年年会 题为“泌尿学新发现：微生物的大数据”，将于 2019年11月7日至10日在新奥尔良市中心万豪酒店会议中心，新奥尔良，洛杉矶。 自1992年以来，该会议每年举行一次，为了解 最新进展的基础，翻译和临床前泌尿学研究，除了提供一个 讨论如何利用这些进展预防和治疗 泌尿系统疾病在过去的十年里，关于分子决定簇和 调节正常和疾病过程的关键途径，以及各种新的治疗和 因此出现了诊断策略。因此，今年的会议将侧重于几个领域， 作为泌尿外科的前沿进展，包括：1）大数据（基因组，转录组，蛋白质组， 和代谢组）分析，这是推动个性化和精准医疗倡议; 2）内分泌和 在泌尿系统疾病中尚未得到充分研究的代谢功能障碍; 3）免疫学和 免疫治疗，泌尿外科是落后于其他领域; 4）良性泌尿系疾病，是重点 几个NIDDK资助的奥布莱恩中心和P20项目; 5） 泌尿学研究;以及6）微生物组和炎症，将我们的知识推向一个新的水平。 此应用程序的支持将用于提供14个旅行奖励，以支持弱势，贫困， 提交研究摘要并希望参加会议的代表和/或初级研究者， 但他们可能无法出席。除了强调最近的进展和确定关键的 知识差距，会议的主要目标包括：1）吸引来自不同领域的领先科学家 促进基础、转化和临床研究科学家之间的互动，从而提供 跨学科交流与合作的框架，以及2）作为青年论坛 科学家与泌尿学研究领域的领先科学家互动，从而增加他们的机会， 积极参与并融入实地。所有33位受邀演讲者都已接受邀请， 在六个全体会议上提供演讲和回答问题，包括：1）大数据作为引擎， 发现; 2）靶向内分泌和代谢功能障碍; 3）免疫学和免疫疗法; 4） 针对良性泌尿系统疾病; 5）泌尿外科创新技术; 6）微生物组和 炎症预计至少有200人参加，我们将招募各种各样的临床医生， 医生，科学家，和基础研究人员与会者，特别强调早期职业生涯的调查人员， 在泌尿外科研究中代表性不足的群体。最后，制定了一项强有力的计划， 会议和支持，如果授予，由NCI和NIDDK。

This application requests support for the Society for Basic Urologic Research (SBUR) 2019 Annual Meeting entitled, “NOVEL DISCOVERIES IN UROLOGY: BIG DATA TO MICROBIOME” which will be held on November 7 - 10, 2019 at the New Orleans Downtown Marriott at the Convention Center, New Orleans, LA. This conference has been held annually since 1992 and provides a unique environment to learn about the most recent advances in basic, translational and preclinical urologic research, in addition to providing a dynamic forum for discussing how these advances could be implemented for the prevention and treatment of urological diseases. Much has been learned over the last decade regarding the molecular determinants and key pathways that regulate normal and disease processes, and a wide variety of novel therapeutic and diagnostic strategies have emerged as a result. Thus, this year’s meeting will focus on a few areas that are emerging as the cutting-edge advances in urology, including: 1) big data (genome, transcriptome, proteome, and metabolome) analysis that is driving the personalized and precision medicine initiative; 2) endocrine and metabolic dysfunctions that have not been well studied in urologic diseases; 3) immunology and immunotherapy that urology is lagging behind other fields; 4) benign urologic disease that is the focus of several NIDDK-funded O’Brien centers and P20 programs; 5) innovative technologies that have emerged in urologic research; and 6) microbiome and inflammation that are pushing forward our knowledge to a new level. The support from this application will be used to provide 14 travel awards to support disadvantaged, poorly represented and/or junior investigators who submit research abstracts and wish to participate in the meeting, but who otherwise might not be able to attend. In addition to highlighting recent advances and identifying key knowledge gaps, the primary goals of the conference include: 1) attracting leading scientists from diverse fields to promote interactions between basic, translational and clinical research scientists thereby providing a framework for cross-disciplinary communication and collaboration, and 2) serving as a forum for young scientists to interact with leading scientists in urologic research leading to enhanced opportunities for their active participation and integration into the field. All 33 invited speakers have already accepted invitations to provide presentations and answer questions in six plenary sessions, including: 1) Big Data as Engines for Discovery; 2) Targeting Endocrine and Metabolic Dysfunctions; 3) Immunology and Immunotherapy; 4) Targeting Benign Urologic Disease; 5) Innovative Technologies in Urology; and 6) Microbiome and Inflammation. An attendance of at least 200 is expected, and we will recruit a large variety of clinician, physician-scientist, and basic researcher attendees, with special emphasis on early-career investigators and groups typically underrepresented in urologic research. Finally, a robust plan is in place for publicizing the conference and the support, if awarded, by NCI and NIDDK.